Advances in the therapy of bacterial bloodstream infections. (February 2020)

• Record Type: Journal Article
• Authors: Giannella, M.; Bartoletti, M.; Gatti, M.; Viale, P.
• Is Part Of: Clinical microbiology and infection. Volume 26:Number 2(2020)
• Page Start: 158
• Page End: 167
• Publication Date: 2020-02
• Subjects: Bloodstream infection -- Combination regimen -- Dosing schedules -- New antibiotics; Medical microbiology -- Periodicals; Diagnostic microbiology -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 616.01
• DOI: 10.1016/j.cmi.2019.11.001
• Languages: English
• ISSNs: 1198-743X

Abstract

Abstract: Background: Advances in the diagnostic and therapeutic management of patients with bloodstream infections (BSIs) have been achieved in the last years, improving clinical outcome. However, mortality associated with some pathogens, such as Staphylococcus aureus and Enterococcus spp., is still high. In addition, the spread of antibiotic resistance, mainly among Gram-negative bacteria, reduces treatment options in some circumstances. Therefore, interest in new drugs, combination regimens and optimal dosing schedules is rising. Objectives: Our aim is to summarize the current evidence on available antibiotic regimens for patients with bacterial BSI, focusing on drug choice, combination regimens and optimal dosing schedules. We selected bacteria that are difficult to manage because of virulence factors (i.e. methicillin-susceptible S. aureus ), tolerance to antibiotic activity (i.e. Enterococcus faecalis ), and/or susceptibility patterns (i.e. methicillin-resistant S. aureus, vancomycin-resistant enterococci, carbapenem-resistant Enterobacteriaceae, multidrug-resistant Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumannii ). Sources: MEDLINE search with English language and publication in the last 5 years as limits. Content and implications: The literature gaps on the use of new drugs, the uncertainties regarding the use of combination regimens, and the need to optimize dosing schedules in some circumstances (e.g. augmented renal clearance, renal replacement therapy, high inoculum BSI sources, and isolation of bacteria showing high MICs) have been revised.